Abstract
Introduction: Pilocytic astrocytoma, a World Health Organization grade 1 tumor, is the most common brain tumor in children between 5 and 14 years of age and the second most common in children younger than 5 and older than 14. Although classical to the cerebellum and hypothalamic regions, it can also arise in the spinal cord. Larotrectinib, a selective inhibitor of tropomyosin receptor kinase, has been effective in pediatric tumors with NTRK fusion mutations in children as young as 1-month-old. Case: We share the case of a 9-month-old boy who presented with a 4-month history of regression of his milestones and severe constipation who was found to have a large spinal pilocytic astrocytoma with multiple intracranial periventricular lesions.
Original language | English (US) |
---|---|
Journal | Child's Nervous System |
DOIs | |
State | Accepted/In press - 2022 |
Keywords
- Larotrectinib
- Pilocytic astrocytoma
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Clinical Neurology